- Trial phase
- Phase 3
- Time to market
- If Phase 3 Alzheimer's succeeds, NDA submission could come in early 2027 (symptomatic) or early 2028 (disease-modifying). Earliest potential FDA approval would be late 2028 at best.
- Why 7/10
- The next hard, dated catalyst is the pivotal Phase 3 Alzheimer's 6-month symptomatic data readout, anticipated in Q1 2027 (~6-8 months from now). This is essentially a make-or-break binary for Annovis, which is a single-asset company. However, the readout is still months away and the Parkinson's Phase 3 program has a mixed track record (missed ITT primary endpoint), tempering the conviction.
Investors should watch for the Q1 2027 Alzheimer's Phase 3 symptomatic readout as the defining catalyst. The company will likely need additional financing before then given ~$14M cash and ~$17M/quarter burn. The Parkinson's miss on ITT primary endpoint is a cautionary precedent. Analyst consensus is strong-buy with $11 mean PT, but that reflects binary-option-like upside rather than de-risked fundamentals.
Price Chart
Executive Summary
Buntanetap is a once-daily oral small-molecule drug being developed by Annovis Bio (NYSE: ANVS) for Alzheimer's and Parkinson's diseases. It has a unique mechanism, it's a translational inhibitor that reduces production of multiple neurotoxic proteins (amyloid beta, tau, alpha-synuclein) simultaneously, unlike approved monoclonal antibodies that target only amyloid after it's formed. The drug has completed Phase 3 in Parkinson's (mixed results, missed ITT primary endpoint but showed signals in subgroups) and has just fully enrolled a pivotal Phase 3 Alzheimer's trial (850 patients) with a symptomatic data readout expected Q1 2027. Annovis is a single-asset company with ~$24M in cash post-April 2026 offering, burning ~$17M/quarter, creating significant financing risk before the next key readout.
How It Works
Buntanetap is a once-daily pill that works by turning down the production of several different toxic proteins that clump up in the brain in Alzheimer's and Parkinson's, specifically amyloid beta, tau, and alpha-synuclein. It does this by helping a natural "brake" protein (IRP1) stay bound to the genetic instructions for these toxic proteins, preventing them from being made. This differs from approved antibody drugs (Leqembi, Kisunla) that are given as IV infusions and try to clear already-formed amyloid clumps after they've been made.
Trial Status
Alzheimer's Disease: Pivotal Phase 3 trial (NCT06709014) reached full enrollment of 850 patients in July 2026. Symptomatic data readout expected Q1 2027, disease-modifying readout Q1 2028. Parkinson's Disease: Phase 3 (NCT05357989) completed; missed primary endpoint in ITT population but showed positive signals in per-protocol and cognitively-impaired subgroups. An open-label safety extension study is ongoing. Phase 2/3 Alzheimer's results published in Nature Portfolio (npj Dementia) April 2026 showing favorable safety and efficacy in mild-to-moderate patients.
The Two-Sided Case
Upcoming Catalysts
- Q1 2027: Phase 3 Alzheimer's 6-month symptomatic data readout, the primary binary catalyst.
- Q1 2028: Phase 3 Alzheimer's 18-month disease-modifying data readout.
- Potential NDA submission for symptomatic Alzheimer's treatment in early 2027 (if Phase 3 positive).
- Parkinson's open-label extension safety study updates.
- Type C FDA meeting outcomes for Parkinson's disease dementia strategy.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Annovis Bio, Inc. 8-K ANVS ·Originating report